Table 3 Predictors of 1-point EDSS improvement in the first year of treatment
From: Clinical baseline factors predict response to natalizumab: their usefulness in patient selection
Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|
OR | CI | P | OR | CI | P | |
Sex (female vs male) | 1.02 | 0.33–3.11 | 0.98 | - | - | - |
Age | 0.1 | 0.94–1.51 | 0.91 | - | - | - |
Disease duration | 1.00 | 0.92–1.09 | 0.91 | - | - | - |
ARR in the pre-treatment year | 1.3 | 0.96–1.95 | 0.21 | - | - | - |
EDSS gain the pre-treatment year | 1.31 | 0.83–2.07 | 0.25 | - | - | - |
EDSS at baseline | 0.91 | 0.68–1.22 | 0.54 | - | - | - |
EDSS at baseline, categorized | 0.04 | 0.056 | ||||
3.0 to 3.5 compared to < = 2.5 | 6.00 | 1.26–28.55 | 0.02 | 5.78 | 1.06–31.50 | 0.04 |
4.0 to 5.5 compared to < = 2.5 | 2.00 | 0.43–9.26 | 0.37 | 0.73 | 0.11–4.8 | 0.74 |
6 and above compared to < = 2.5 | 0.69 | 0.13–3.75 | 0.67 | 0.59 | 0.08–4.2 | 0.59 |
High pre-treatment disease activity | 4.58 | 1.25–16.76 | 0.02 | 4.80 | 1.00–23.08 | 0.05 |